EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Improved patient‐ and caregiver‐reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitis

Julie Ryan Wolf iD, Anita Chen, Jill Wieser, Brad Johnson, Lauren Baughman, Gayin Lee, Eleanor Pope, Abigail Franco, Tanzy Love, Lisa A Beck iD

Journal of the European Academy of Dermatology and Venereology · 2024

DOI: 10.1111/jdv.19807 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von Julie Ryan Wolf und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Rochester Medical Center, Rochester, New York, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Tacrolimus, Boron Compounds, Caregivers. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIEHS NIH HHS, NCATS NIH HHS, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atopic dermatitis (AD) is a chronic skin disease that affects 20% of children worldwide and is associated with low patient‐reported quality of life (QoL). Crisaborole (CRIS) and tacrolimus 0.03% (TAC) are Food and Drug Administration (FDA)‐approved topical treatments for mild to moderate AD with similar clinical efficacy. Utilization of patient‐reported outcomes (PROs) may provide meaningful data on the impact of AD treatments on patients and caregivers. This study used PROs to monitor the impact of crisaborole (CRIS) and tacrolimus 0.03% (TAC) on children with mild/moderate atopic dermatitis (AD) and caregiver burden.

Methods

This open‐label study randomized 47 child‐caregiver dyads to CRIS or TAC for 12 weeks. Disease severity, child quality of life (QoL), itch, pain interference, anxiety, depression, sleep, caregiver burden and caregiver QoL were assessed at baseline, 6 and 12 weeks.

Results

A total of 36 dyads completed the study. Children (mean age = 8.0 ± 3.9 years) had mild baseline AD and were diverse by race (39% white; 36% Black) and gender (53% males). Caregivers were mostly female (78%; mean age = 37 ± 7.6 years). Both arms improved disease severity (Eczema Area and Severity Index) from baseline to 12 weeks (CRIS = −2.4 vs. TAC = −1.9). Within‐arm analyses comparing baseline to 12 weeks revealed TAC, but not CRIS, improved all child and caregiver PROs except sleep (all p < 0.05).

Conclusions

Our results demonstrated that topical treatment for 12 weeks was more beneficial than 6 weeks, with TAC improving more PROs than CRIS. Future trials should implement PROs to fully understand the impact of AD treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicTacrolimusBoron CompoundsCaregiversQuality of LifePatient Reported Outcome MeasuresBridged Bicyclo Compounds, HeterocyclicHumansChildFemaleMaleChild, PreschoolSeverity of Illness IndexPruritusAnxietyAdolescentDepressionSleepPainImmunosuppressive Agents

Substanzen

TacrolimusBoron CompoundscrisaboroleBridged Bicyclo Compounds, HeterocyclicImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Dermatology, University of Rochester Medical Center, Rochester, New York, USA.
  • Department of Biostatistics & Computational Biology, University of Rochester Medical Center, Rochester, New York, USA.

ORCID-Profile: Julie Ryan Wolf, Lisa A Beck

Förderung

  • NIEHS NIH HHS
  • NCATS NIH HHS
  • Pfizer
  • National Center for Advancing Translational Sciences

Zitieren

APA

Ryan Wolf, J., Chen, A., Wieser, J., Johnson, B., Baughman, L., Lee, G., Pope, E., Franco, A., Love, T., & Beck, L. A. (2024). Improved patient‐ and caregiver‐reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitis. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19807

Vancouver

Ryan Wolf J, Chen A, Wieser J, Johnson B, Baughman L, Lee G, et al. Improved patient‐ and caregiver‐reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitis. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19807

BibTeX
@article{RyanWolf2024,
  author = {Ryan Wolf, Julie and Chen, Anita and Wieser, Jill and Johnson, Brad and Baughman, Lauren and Lee, Gayin and Pope, Eleanor and Franco, Abigail and Love, Tanzy and Beck, Lisa A},
  title = {Improved patient‐ and caregiver‐reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitis},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2024},
  doi = {10.1111/jdv.19807}
}
Kostenlos starten →